"Immunotherapy, Active" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Active immunization where vaccine is administered for therapeutic or preventive purposes. This can include administration of immunopotentiating agents such as BCG vaccine and Corynebacterium parvum as well as biological response modifiers such as interferons, interleukins, and colony-stimulating factors in order to directly stimulate the immune system.
| Descriptor ID |
D016233
|
| MeSH Number(s) |
E02.095.465.425.400.530 E05.478.550.600
|
| Concept/Terms |
Immunotherapy, Active- Immunotherapy, Active
- Active Immunotherapy
- Active Immunotherapies
- Immunotherapies, Active
Vaccine Therapy- Vaccine Therapy
- Therapy, Vaccine
- Therapies, Vaccine
- Vaccine Therapies
Immune RNA Manipulation- Immune RNA Manipulation
- Immune RNA Manipulations
- Manipulation, Immune RNA
- Manipulations, Immune RNA
- RNA Manipulation, Immune
- RNA Manipulations, Immune
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Active".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Active".
This graph shows the total number of publications written about "Immunotherapy, Active" by people in this website by year, and whether "Immunotherapy, Active" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy, Active" by people in Profiles.
-
Melchior B, Garcia AE, Hsiung BK, Lo KM, Doose JM, Thrash JC, Stalder AK, Staufenbiel M, Neumann H, Carson MJ. Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer's disease. ASN Neuro. 2010 Jul 12; 2(3):e00037.
-
Nguyen LT, Elford AR, Murakami K, Garza KM, Schoenberger SP, Odermatt B, Speiser DE, Ohashi PS. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med. 2002 Feb 18; 195(4):423-35.
-
Mitchell MS, Liggett PE, Green RL, Kan-Mitchell J, Murphree AL, Dean G, Spears L, Walonker F. Sustained regression of a primary choroidal melanoma under the influence of a therapeutic melanoma vaccine. J Clin Oncol. 1994 Feb; 12(2):396-401.
-
Mitchell MS, Harel W, Kan-Mitchell J, LeMay LG, Goedegebuure P, Huang XQ, Hofman F, Groshen S. Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action. Ann N Y Acad Sci. 1993 Aug 12; 690:153-66.
-
Kan-Mitchell J, Huang XQ, Steinman L, Oksenberg JR, Harel W, Parker JW, Goedegebuure PS, Darrow TL, Mitchell MS. Clonal analysis of in vivo activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapy. Cancer Immunol Immunother. 1993 Jul; 37(1):15-25.